Alkane Resources And 2 Australian Penny Stocks To Watch

Inflation remains the key focus for central banks, with US policymakers openly tying future rate moves to stubborn price pressures. Higher borrowing costs can squeeze heavily indebted minnows. Australian low-priced shares that pair small size with healthier balance sheets look more insulated. That creates a hunting ground for investors who want penny stocks without pure speculation. This article highlights three such opportunities from our financially robust penny share universe.

The three stocks highlighted here offer a compelling starting point if you want exposure to lower risk early-stage businesses with stronger financial footing. However, if you want the names that matter most, these 18 elite penny stocks are the strongest companies we've found.

Alkane Resources (ASX:ALK)

Overview: Alkane Resources is an Australian multi-mine gold producer, anchored by the Tomingley operation, with additional exposure to copper, nickel, zinc, silver and junior gold investments that support its financially focused penny stock profile.

Operations: Alkane Resources generated A$417 million from Tomingley, A$270 million from Costerfield and A$249 million from Bjorkdal, all in Australia, totalling about A$936 million in revenue.

Market Cap: A$2.46b

Alkane Resources fits the Financially Fit Penny Stocks theme because its producing gold assets provide cash flow rather than being purely exploration-focused. RTRockeTeller, a Simply Wall St Community investor who wrote a detailed narrative on the stock, argues that this shift to a multi-mine platform changes the overall risk profile.

"The main risk is that Alkane is now a more complex business. Instead of one operation, investors must understand three mines, three jurisdictions, different cost structures, underground mining risk, antimony market volatility, and a large future capex project at Boda-Kaiser."

The extent of Alkane Resources’ appeal within a financially focused penny universe depends heavily on how one unseen cost pressure evolves.

Those moving parts sit at the heart of the risk question, and the full narrative for Alkane Resources shows how Alkane Resources could turn that complexity into increasing optionality for patient investors.

DroneShield (ASX:DRO)

Overview: DroneShield develops and sells counter-drone hardware and software like DroneSentry and DroneGun that help military, security and infrastructure clients protect airspace.

Operations: DroneShield generates about A$270 million from Aerospace & Defense solutions, largely across Australia and the rest of the world at A$243 million.

Market Cap: A$1.09 billion

For the Financially Fit Penny Stocks theme, DroneShield matters because its core counter-drone systems already bring in real contract revenue rather than relying purely on early concept sales. According to danmad, an investor in the Simply Wall St Community, that transition toward recurring defence procurement is where the bigger opportunity could sit.

"If management continues converting its growing pipeline into multi-year contracts while expanding margins through scale manufacturing, we could see a valuation re-rating over the next 12 to 24 months."

What happens to DroneShield’s appeal in this screen depends heavily on how one emerging pressure around contract quality and repeat orders resolves.

How that contract quality plays out is exactly what the full narrative for DroneShield unpacks, distinguishing one-off wins from opportunities for accelerating repeat business.

Sigma Healthcare (ASX:SIG)

Overview: Sigma Healthcare runs a large wholesale and distribution network supplying franchised pharmacies like Chemist Warehouse, Amcal, Discount Drug and PriceSave, plus medication-management services. This provides the cash-generating backbone that ties it to the Financially Fit Penny Stocks theme.

Operations: Sigma Healthcare generated about A$10.8b from healthcare products, with roughly A$10.4b in Australia and A$421 million from international markets.

Market Cap: A$33.2b

Sigma Healthcare matters for this financially focused penny stock theme because its pharmacy wholesale and retail network generates sizeable everyday transaction revenue. The bearish analyst narrative on Simply Wall St argues that the way Sigma builds out higher margin own-label products could be just as important as headline growth.

"Although expansion of owned and exclusive label products is approaching A$1b of sales and carries structurally higher margins, the larger inventory required, combined with a longer cash conversion cycle at 54 days, creates working capital pressure."

What happens if a single assumption about that balance between richer categories and the cash locked in shelves starts to break?

If that trade off is what you care about, the full narrative for Sigma Healthcare shows how Sigma Healthcare could turn working capital strain into accelerating pharmacy network strength.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. By the time momentum headlines hit, early entries are already flying. Scan these under the radar lists while it matters and act now.

• Spot income workhorses that aim to keep paying investors even when sentiment drops by reviewing the 4 dividend fortresses curated from cleaner balance sheets and consistent cash profiles.
• Track structural power demand as grids upgrade for EVs and AI by checking the 43 power grid technology and infrastructure stocks before capital chases the next infrastructure breakout.
• Consider the copper story if electrification continues to expand by assessing the 17 top copper producer stocks while these producers are still flying under broader market attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com